Repositioning Candidate Details
| Candidate ID: | R1490 |
| Source ID: | DB13346 |
| Source Type: | approved; withdrawn |
| Compound Type: | small molecule |
| Compound Name: | Bufexamac |
| Synonyms: | 2-(p-Butoxyphenyl)-acetohydroxamic acid; 4-Butoxy-N-hydroxybenzeneacetamide; 4-Butoxyphenylacetohydroxamic acid; Bufexamac; Bufexamic acid; p-Butoxyphenylacetohydroxamic acid |
| Molecular Formula: | C12H17NO3 |
| SMILES: | CCCCOC1=CC=C(CC(=O)NO)C=C1 |
| Structure: |
|
| DrugBank Description: | Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac. It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns, and itching. It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization . Bufexamac was also withdrawn by the EMA in April 2010. |
| CAS Number: | 2438-72-4 |
| Molecular Weight: | 223.272 |
| DrugBank Indication: | Indicated for the treatment of various skin conditions, such as atopic eczema and other inflammatory dermatoses. |
| DrugBank Pharmacology: | Bufexamac is a topically-active anti-inflammatory agent that inhibits the cyclooxygenase enzyme. In cutaneous and deep experimental inflammation, topical administration of bufexamac exerted a dose-related anti-inflammatory effect . In guinea pigs, bufexamax was shown to be more active than topical acetylsalicylic acid 5% or phenylbutazone 5% in delaying the local increase in temperature resulting from UV exposure . Bufexamac is unlikely to have any effect on wound healing . |
| DrugBank MoA: | The full mechanism of action is unclear. It is proposed that bufexamac acts similarly to other non-steroidal anti-inflammatory drugs to inhibit prostaglandin biosynthesis _in vitro_, via inhibiting cyclo-oxygenase (COX) enzymes . Systematically administered bufexamac may accumulate preferentially in the adrenal cortex of rats and may play a role in adrenal stimulation; however its topical anti-inflammatory action is likely to be independent of this effect . |
| Targets: | Prostaglandin G/H synthase 1 inhibitor; Prostaglandin G/H synthase 2 inhibitor; Histone deacetylase 6 inhibitor; Histone deacetylase 10 inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|